Interaction of Caffeine With Regadenoson-Induced Hyperemic Myocardial Blood Flow as Measured by Positron Emission Tomography
Open accessAI snapshot
Written from the paper’s full text.
TL;DR
In a randomized, double-blind, placebo-controlled crossover trial in 41 healthy volunteers, 200 mg caffeine did not significantly alter regadenoson-induced hyperemic myocardial blood flow or coronary flow reserve. Caffeine did raise resting heart rate and blood pressure and blunted regadenoson-induced heart-rate increase, while improving tolerability.
Key findings
- Resting MBF: caffeine 1.13 ± 0.04 vs placebo 1.06 ± 0.05 ml/min/g; stress MBF: 2.98 ± 0.14 vs 3.05 ± 0.14 ml/min/g; CFR: 2.75 ± 0.16 vs 2.97 ± 0.16, p = NS. The data show with 1-sided 95% confidence that any CFR reduction associated with caffeine is <20%.
- Caffeine increased resting HR (65 ± 11 vs 61 ± 9 beats/min, p < 0.05), systolic BP (118 ± 11 vs 112 ± 10 mm Hg, p < 0.001), and diastolic BP (73 ± 6 vs 70 ± 7 mm Hg, p < 0.001). Regadenoson-induced HR increase was blunted by 20 beats/min (p < 0.001) after caffeine; BP was not significantly affected.
- No serious adverse events were reported. Most frequent adverse events were dyspnea (56%), palpitations (49%), flushing (30%), headache (28%), sensation of heaviness (28%), and paresthesia (19%). Caffeine did not change incidence but improved tolerability and attenuated adverse event severity.
Methods
- Phase II, double-blind, randomized, placebo-controlled crossover study in 41 healthy volunteers (15 female), age 18 years or older, nonsmokers, and regular coffee drinkers. They received 200 mg caffeine or placebo on Day 1 and the other on Day 2 after refraining from methylxanthine-containing products for at least 24 h; washout was 2 to 14 days.
- MBF was measured 2 h after capsule ingestion by PET with 15O-labeled water at rest and immediately after intravenous regadenoson (400 g over 10 s, as printed). CFR was calculated as hyperemic over resting MBF.
- Continuous variables summarized as mean and SD or SE were compared using analysis of variance; p < 0.05 was significant. Sequence and period values were comparable, so all data were pooled.
Limitations
- Stated: further study in patients with coronary artery disease and possibly at higher caffeine doses would be required before definitive conclusions could be drawn.
- Evident from the text: findings are limited to healthy volunteers (mean age 27 ± 6 years), a single 200 mg caffeine dose, and no clinical CAD population; the report is a letter with limited methodological detail.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 11 cited sources checked · 0 supported · 0 flagged
- Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
The data show with 1-sided 95% confidence that any CFR reduction associated with caffeine intake is less than 20%.
“The data show with 1-sided 95% confidence that any CFR reduction associated with caffeine intake is Ͻ20%.”
Quote in the paperSubstantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Heart rate during resting MBF was higher after caffeine compared with placebo.
“Heart rate (HR) Ϯ SD during resting MBF was higher after caffeine as compared with placebo (65 Ϯ 11 beats/min vs. 61 Ϯ 9 beats/min, p Ͻ 0.05).”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Caffeine pretreatment was associated with improved tolerability of regadenoson.
“Caffeine pretreatment did not change the incidence of adverse events but was associated with improved tolerability (as assessed by a questionnaire) and attenuation of adverse event severity.”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Diastolic blood pressure was higher after caffeine compared with placebo.
“Similarly, systolic (118 Ϯ 11 mm Hg vs. 112 Ϯ 10 mm Hg, p Ͻ 0.001) and diastolic (73 Ϯ 6 mm Hg vs. 70 Ϯ 7 mm Hg, p Ͻ 0.001) blood pressure were higher after caffeine versus placebo.”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
MBF at stress was not significantly different between caffeine and placebo.
“The MBF Ϯ SE was not significantly different between caffeine and placebo at rest (1.13 Ϯ 0.04 ml/min/g vs. 1.06 Ϯ 0.05 ml/min/g) and stress (2.98 Ϯ 0.14 ml/min/g vs. 3.05 Ϯ 0.14 ml/min/g).”
Quote in the paperSubstantial claim
- Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Blood pressure was not significantly affected by prior caffeine ingestion.
“The HR increase induced by regadenoson was blunted by 20 beats/min (p Ͻ 0.001) after caffeine, whereas blood pressure was not significantly affected by prior caffeine ingestion.”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Systolic blood pressure was higher after caffeine compared with placebo.
“Similarly, systolic (118 Ϯ 11 mm Hg vs. 112 Ϯ 10 mm Hg, p Ͻ 0.001) and diastolic (73 Ϯ 6 mm Hg vs. 70 Ϯ 7 mm Hg, p Ͻ 0.001) blood pressure were higher after caffeine versus placebo.”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Caffeine pretreatment was associated with attenuation of adverse event severity.
“Caffeine pretreatment did not change the incidence of adverse events but was associated with improved tolerability (as assessed by a questionnaire) and attenuation of adverse event severity.”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
MBF at rest was not significantly different between caffeine and placebo.
“The MBF Ϯ SE was not significantly different between caffeine and placebo at rest (1.13 Ϯ 0.04 ml/min/g vs. 1.06 Ϯ 0.05 ml/min/g) and stress (2.98 Ϯ 0.14 ml/min/g vs. 3.05 Ϯ 0.14 ml/min/g).”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Regadenoson-induced CFR was comparable with and without caffeine.
“Consequently, the regadenoson-induced CFR was comparable with and without caffeine (2.75 Ϯ 0.16 vs. 2.97 Ϯ 0.16, p ϭ NS) (Fig. 1).”
Quote in the paperSubstantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
The heart rate increase induced by regadenoson was blunted by 20 beats/min after caffeine.
“The HR increase induced by regadenoson was blunted by 20 beats/min (p Ͻ 0.001) after caffeine, whereas blood pressure was not significantly affected by prior caffeine ingestion.”
Quote in the paperNot a substantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Baseline caffeine levels were comparable on the two study days.
“Baseline caffeine levels Ϯ SE were comparable on the 2 study days (0.36 Ϯ 0.09 mg/l vs. 0.23 Ϯ 0.09 mg/l) and increased significantly after caffeine, but not after placebo (4.26 Ϯ 0.18 mg/l vs. 0.33 Ϯ 0.18 mg/l).”
Quote in the paperSubstantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Resting and hyperemic MBF and CFR values were comparable irrespective of sequence or period.
“All resting and hyperemic MBF as well as CFR values were comparable irrespective of the sequence (caffeine/placebo or placebo/caffeine) or period (Day 1 or 2).”
Quote in the paperSubstantial claim - Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Caffeine pretreatment did not change the incidence of adverse events.
“Caffeine pretreatment did not change the incidence of adverse events but was associated with improved tolerability (as assessed by a questionnaire) and attenuation of adverse event severity.”
Quote in the paperNot a substantial claim - Interpretationnone given§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
The present study is the first to report the effect of caffeine on coronary hyperemia induced by a selective adenosine agonist in humans.
“The present study is the first to report the effect of caffeine on coronary hyperemia induced by a selective adenosine agonist in humans.”
Quote in the paperNot a substantial claim - Premisecitation§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Previous studies found a dose-dependent attenuation of adenosine-induced and dipyridamole-induced CFR by caffeine.
“Previous studies found a dose-dependent attenuation of adenosine-induced and dipyridamole-induced CFR by caffeine (4).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [4] Lapeyre, 2004, The impact of caffeine on vasodilator stress perfusion studies, J Nucl Cardiol source
Not checked in the free run.
- Interpretationown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Regadenoson-induced CFR remained above 2.0 for the majority of subjects after prior caffeine ingestion (200 mg).
“It suggests that regadenoson-induced CFR was not significantly affected by prior caffeine ingestion (200 mg) and remained above 2.0 for the majority of subjects.”
Quote in the paperSubstantial claim
- May combine two claims. 14
- Classified as probably not a substantial claim. 8
May combine two claims.
Findingnone given§ Regadenoson increases MBF by acting on coronary A 2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A 2A receptors.Overall, regadenoson was well tolerated; side effects were generally mild or moderate in severity and all self-limiting.
“Overall, regadenoson was well tolerated; side effects were generally mild or moderate in severity and all self-limiting.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialNo serious adverse event was reported.
“No serious adverse event was reported.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingreasoning§ Regadenoson increases MBF by acting on coronary A 2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A 2A receptors.Caffeine attenuated the severity of side effects and improved tolerability of regadenoson.
“Caffeine attenuated the severity of side effects and improved tolerability of regadenoson.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialThe most frequent adverse events were dyspnea (56%), palpitations (49%), flushing (30%), headache (28%), sensation of heaviness (28%), and paresthesia (19%).
“The most frequent adverse events were dyspnea (56%), palpitations (49%), flushing (30%), headache (28%), sensation of heaviness (28%), and paresthesia (19%).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialCaffeine levels increased significantly after caffeine but not after placebo.
“Baseline caffeine levels Ϯ SE were comparable on the 2 study days (0.36 Ϯ 0.09 mg/l vs. 0.23 Ϯ 0.09 mg/l) and increased significantly after caffeine, but not after placebo (4.26 Ϯ 0.18 mg/l vs. 0.33 Ϯ 0.18 mg/l).”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
Premisecitation§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialRegadenoson selectively dilates coronary relative to peripheral vascular beds, potentially due to high density of coronary A2A receptors, and activation of a small percentage of these receptors evokes maximal dilation.
“It selectively dilates coronary relative to peripheral vascular beds, potentially due to the high density of coronary A 2A receptors, and activation of a small percentage of these receptors evokes maximal dilation (2).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [2] Shryock, 1998, A2A-adenosine receptor reserve for coronary vasodilation, Circulation source
Not checked in the free run.
May combine two claims.
Premisecitation§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialCaffeine is a nonselective competitive A2A receptor antagonist and its use has been contraindicated before vasodilator MPI because it attenuates coronary hyperemia caused by adenosine and dipyridamole in a dose-dependent manner.
“The use of caffeine, a nonselective competitive A 2A receptor antagonist, has been contraindicated before vasodilator MPI (3) because it attenuates the coronary hyperemia caused by the nonselective adenosine receptor agonists adenosine and dipyridamole in a dose-dependent manner (4).”
Quote in the paperSubstantial claim0 of 2 sources checkedClassified as probably not a substantial claim. May combine two claims.
Premisecitation§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialRegadenoson is a selective A2A adenosine receptor agonist under investigation as a pharmacologic vasodilator in nuclear stress myocardial perfusion imaging (MPI).
“Regadenoson is a selective A 2A adenosine receptor agonist under investigation as a pharmacologic vasodilator in nuclear stress myocardial perfusion imaging (MPI) (1).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Hendel, 2005, Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging, J Am Coll Cardiol source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
Premisecitation§ Regadenoson increases MBF by acting on coronary A 2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A 2A receptors.There is a higher receptor reserve for coronary A2A agonist-mediated coronary vasodilation, and 25% occupancy by regadenoson translates into 90% maximal vasodilation.
“There is a higher receptor reserve for coronary A 2A agonist-mediated coronary vasodilation, and 25% occupancy by regadenoson translates into 90% maximal vasodilation.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [2] Shryock, 1998, A2A-adenosine receptor reserve for coronary vasodilation, Circulation source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone given§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialTwenty-one volunteers in the placebo/caffeine sequence and 20 in the caffeine/placebo sequence completed the study.
“Twenty-one volunteers in the placebo/caffeine sequence and 20 in the caffeine/placebo sequence completed the study.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationreasoning§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialCaffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson.
“Therefore, it seems that caffeine blunts the vasodilatory effect of adenosine but has a limited effect on regadenoson.”
Quote in the paperSubstantial claim- Rests on an assumption: Regadenoson has a higher affinity for A2A receptors than adenosine and is a more potent coronary vasodilator.
Classified as probably not a substantial claim.
Study design and conductown data§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialAll subjects returned for the second study day after a washout period of 2 to 14 days.
“All subjects (mean age Ϯ SD 27 Ϯ 6 years) returned for the second study day after a washout period (2 to 14 days).”
Quote in the paperSubstantial claimClassified as probably not a substantial claim. May combine two claims.
Premisecitation§ Regadenoson increases MBF by acting on coronary A 2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A 2A receptors.The interaction of caffeine with adenosine-induced, dipyridamole-induced, and exercise-induced MBF changes may limit correct detection of coronary artery disease and proper management, leading to recommendation to withhold caffeine for 24 h before vasodilator stress testing.
“The interaction of caffeine with adenosine-induced, dipyridamoleinduced, and even exercise-induced MBF changes (4,6) may limit the correct detection of coronary artery disease and subsequently the proper management of the patient, leading to the general recommendation to withhold caffeine for 24 h before vasodilator stress testing (3).”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [4] Lapeyre, 2004, The impact of caffeine on vasodilator stress perfusion studies, J Nucl Cardiol source
Not checked in the free run.
- cites [6] Namdar, 2006, Caffeine decreases exercise-induced myocardial flow reserve, J Am Coll Cardiol source
Not checked in the free run.
- cites [3] Klocke, 2003, J Am Coll Cardiol source
Not checked in the free run.
May combine two claims.
Premisecitation§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialRegadenoson has a higher A2A receptor affinity and higher receptor reserve compared with adenosine, and is administered as a bolus.
“This may be explained by the fact that regadenoson has a higher A 2A receptor affinity (7) and higher receptor reserve (2) compared with adenosine, and is administered as a bolus (as opposed to a 6-min infusion for adenosine).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [7] Eggbrecht, 2006, Regadenoson (CV Therapeutics/Astellas), Curr Opin Investig Drugs
Not checked in the free run.
- cites [2] Shryock, 1998, A2A-adenosine receptor reserve for coronary vasodilation, Circulation source
Not checked in the free run.
May combine two claims.
Interpretationreasoning§ A Randomized, Double-Blind, Placebo-Controlled Crossover TrialRegadenoson may lead to a higher A2A receptor occupancy and vasodilator effect compared with adenosine.
“Therefore, regadenoson may lead to a higher A 2A receptor occupancy and vasodilator effect compared with adenosine.”
Quote in the paperSubstantial claim- Rests on an assumption: Regadenoson has a higher affinity for A2A receptors than adenosine and is a more potent coronary vasodilator.
Classified as probably not a substantial claim. May combine two claims.
Interpretationreasoning§ Regadenoson increases MBF by acting on coronary A 2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A 2A receptors.If the effects of caffeine are inversely proportional to the receptor reserve, then the higher receptor reserve required to dilate coronary vessels than to increase HR may explain that caffeine significantly blunted the increase in HR but had a limited effect on MBF caused by regadenoson.
“If the effects of caffeine are inversely proportional to the receptor reserve, then the higher receptor reserve required to dilate coronary vessels than to increase HR may explain that caffeine significantly blunted the increase in HR but had a limited effect on MBF caused by regadenoson.”
Quote in the paperSubstantial claim- Rests on an assumption: Regadenoson increases MBF by acting on coronary A2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A2A receptors.
The paper relies on this without support.
Regadenoson has a higher affinity for A2A receptors than adenosine and is a more potent coronary vasodilator.
“It has a higher affinity for A 2A receptors than adenosine and is a more potent coronary vasodilator.”
The paper relies on this without support.
Regadenoson increases MBF by acting on coronary A2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A2A receptors.
“Regadenoson increases MBF by acting on coronary A 2A receptors, and it increases HR by acting on both chemosensory neurons and peripheral vascular A 2A receptors.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Gaemperli et al. 2008 found that myocardial blood flow was not significantly different between caffeine and placebo at rest (1.13 ± 0.04 versus 1.06 ± 0.05 mL/min per g) or under stress (2.98 ± 0.14 versus 3.05 ± 0.14 mL/min per g), and there was no difference in myocardial flow reserve (2.75 ± 0.16 versus 2.97 ± 0.16 mL/min per g); the data show with one-sided 95% confidence that any myocardial
“The MBF (mean ± standard error of the mean (SEM)) was not significantly different between caffeine and placebo at rest (1.13 ± 0.04 mL/min per g versus 1.06 ± 0.05 mL/min per g) or under stress (2.98 ± 0.14 mL/min per g versus 3.05 ± 0.14 mL/min per g).There was no difference in MFR between caffeine and placebo (2.75 ± 0.16 mL/min per g versus 2.97 ± 0.16 mL/min per g).The data show with one-sided”
From Scientific Opinion on the safety of caffeine (2015) · cites this paper as Gaemperli et al., 2008
Cites
ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary
Klocke, F. J., Baird, M. G., Lorell, B. H., Bateman, T. M., Messer, J. V., Berman, D. S., O’Gara, P. T., Carabello, B. A., Russell, R. O., Cerqueira, M. D., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.011 · Cited by 1,303 · see citing works
A <sub>2A</sub> -Adenosine Receptor Reserve for Coronary Vasodilation
Shryock, J. C., Snowdy, S., Baraldi, P. G., Cacciari, B., Spalluto, G., Monopoli, A., Ongini, E., Baker, S. P., & Belardinelli, L. (1998) · Circulation · doi:10.1161/01.cir.98.7.711 · Cited by 199 · see citing works
Hendel, R. C., Bateman, T. M., Cerqueira, M. D., Iskandrian, A. E., Leppo, J. A., Blackburn, B., & Mahmarian, J. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.097 · Cited by 128 · see citing works
Zoghbi, G. J., Htay, T., Aqel, R. A., Blackmon, L., Heo, J., & Iskandrian, A. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.088 · Cited by 65 · see citing works
Caffeine decreases exercise-induced myocardial flow reserve
Namdar, M., Koepfli, P., Grathwohl, R., Siegrist, P. T., Klainguti, M., Schepis, T., Delaloye, R., Wyss, C. A., Fleischmann, S. P., Gaemperli, O., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.064 · Cited by 60 · cited 3× · see citing works
“Because the hyperemic MBF response to regadenoson after caffeine administration lies well within the range of reported response to nonselective adenosine receptor agonists and bicycle stress (6), the present study suggests that regadenoson causes coronary hyperemia with and without prior caffeine ingestion in healthy…”
BackgroundMethodSelf-citationThe impact of caffeine on vasodilator stress perfusion studies
Lapeyre, A. C., Goraya, T. Y., Johnston, D. L., & Gibbons, R. J. (2004) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2004.04.003 · Cited by 39 · see citing works
“One” Cup of Coffee and Nuclear SPECT to Go
Bangalore, S., Parkar, S., & Messerli, F. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.044 · Cited by 14 · see citing works
Regadenoson (CV Therapeutics/Astellas).
Eggbrecht, H., & Gössl, M. (2006) · PubMed · Cited by 7 · see citing works
Flagged first, then by citations
1 of the 9 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers
Henzlova, M. J., Duvall, W. L., Einstein, A. J., Travin, M. I., & Verberne, H. J. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0387-x · Cited by 700 · see citing works
Scientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613 · see citing works
“15 O-labelled water and PET were also used to assess the effects of caffeine on resting and regadenoson-induced hyperaemic MBF, and the resulting MFR, in a double-blind, randomised, placebo-controlled cross-over study (Gaemperli et al., 2008).”
MethodRegadenoson: A New Myocardial Stress Agent
Jaroudi, W. A. A., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.089 · Cited by 219 · see citing works
DePuey, E. G., Mahmarian, J. J., Miller, T. D., Einstein, A. J., Hansen, C. L., Holly, T. A., Miller, E. J., Polk, D. M., & Wann, L. S. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9523-z · Cited by 117 · see citing works
Anatomy and physiology of coronary blood flow
Schelbert, H. R. (2010) · Journal of Nuclear Cardiology · doi:10.1007/s12350-010-9255-x · Cited by 108 · see citing works
Patel, A. R., Bamberg, F., Branch, K. R., et al. (2019) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2019.10.003 · Cited by 87 · see citing works
Selective adenosine agonists and myocardial perfusion imaging
Zoghbi, G. J., & Iskandrian, A. E. (2011) · Journal of Nuclear Cardiology · doi:10.1007/s12350-011-9474-9 · Cited by 71 · see citing works
Advances in Pharmacologic Stress Agents: Focus on Regadenoson
Johnson, S. G., & Peters, S. (2010) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.109.065581 · Cited by 55 · see citing works
“(44) investigated the effects of caffeine on myocardial blood flow during regadenoson stress.”
BackgroundHigh-Dose Adenosine Overcomes the Attenuation of Myocardial Perfusion Reserve Caused by Caffeine
Reyes, E., Loong, C. Y., Harbinson, M., Donovan, J., Anagnostopoulos, C., & Underwood, S. R. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.052 · Cited by 52 · see citing works
Garnock-Jones, K. P., & Curran, M. P. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/10489040-000000000-00000 · Cited by 48 · see citing works
Goudarzi, B., Fukushima, K., Bravo, P. E., Merrill, J., & Bengel, F. M. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1853-6 · Cited by 47 · see citing works
“16, which did not change significantly after caffeine administration [23].”
BackgroundTejani, F. H., Thompson, R. C., Kristy, R., & Bukofzer, S. (2014) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-014-0419-7 · Cited by 37 · see citing works
“A previous study showed that moderate oral caffeine intake (200 mg) did not significantly affect regadenoson-induced myocardial blood flow as assessed by positron emission tomography (PET) in 41 healthy individuals [9].”
BackgroundPET and PET/CT in cardiovascular disease
Gaemperli, O., & Kaufmann, P. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06030.x · Cited by 31 · see citing works
Self-citationThe emerging role of the selective A2A agonist in pharmacologic stress testing
Gemignani, A. S., & Abbott, B. (2010) · Journal of Nuclear Cardiology · doi:10.1007/s12350-010-9211-9 · Cited by 28 · see citing works
van Dijk, R., Kuijpers, D., Kaandorp, T. A. M., van Dijkman, P. R. M., Vliegenthart, R., van der Harst, P., & Oudkerk, M. (2017) · International journal of cardiac imaging · doi:10.1007/s10554-017-1157-4 · Cited by 27 · see citing works
“showed that, in positron emission tomography (PET) imaging, ingestion of a 200 mg caffeine capsule 2 h prior to regadenoson stress perfusion imaging had no significant effect on the pharmacological response as measured by the increase in myocardial blood flow during stress [16].”
BackgroundKitkungvan, D., Bui, L., Johnson, N. P., Patel, M., Roby, A. E., Vejpongsa, P., Babar, A. K., Madjid, M., Nacimbene, A., Kumar, S., et al. (2019) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jez080 · Cited by 25 · see citing works
Positron Emission Tomography in the Diagnosis and Management of Coronary Artery Disease
Kazakauskaitė, E., Žaliaduonytė-Pekšienė, D., Rumbinaitė, E., et al. (2018) · Medicina · doi:10.3390/medicina54030047 · Cited by 23 · see citing works
Palani, G., & Ananthasubramaniam, K. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e3182613db6 · Cited by 23 · see citing works
Regadenoson Stress Testing: A Comprehensive Review With a Focused Update
Elkholy, K. O., Hegazy, O., Okunade, A., Aktas, S., & Ajibawo, T. (2021) · Cureus · doi:10.7759/cureus.12940 · Cited by 20 · see citing works
“The increased CBF occurs in a dose-dependent manner, with maximal dilatation seen when only 25% of the receptors are bound by regadenoson [14-15].”
BackgroundThe effect of caffeine on adenosine myocardial perfusion imaging: Time to reassess?
Hage, F. G., & Iskandrian, A. E. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9519-8 · Cited by 19 · see citing works
Saab, R., Bajaj, N. S., & Hage, F. G. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0364-4 · Cited by 16 · see citing works
Tejani, F. H., Thompson, R. C., Iskandrian, A. E., McNutt, B. E., & Franks, B. (2010) · Journal of Nuclear Cardiology · doi:10.1007/s12350-010-9311-6 · Cited by 16 · see citing works
Farhad, H., & Murthy, V. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.06.004 · Cited by 13 · see citing works
Kero, T., Saraste, A., Lagerqvist, B., Sörensen, J., Pikkarainen, E., Lubberink, M., & Knuuti, J. M. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02731-6 · Cited by 12 · see citing works
Caffeine reduces the sensitivity of vasodilator MPI for the detection of myocardial ischaemia: Pro
Reyes, E. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0371-5 · Cited by 11 · see citing works
Bengalorkar, G. M., Bhuvana, K., Sarala, N., & Kumar, T. (2012) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.97177 · Cited by 11 · see citing works
Pitfalls and Limitations of Radionuclide and Hybrid Cardiac Imaging
Travin, M. I. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.02.003 · Cited by 9 · see citing works
“saw no effect of 200-mg caffeine on (15)O-labeled water–measured coronary flow reserve.(39) However, these studies all had small”
BackgroundRegadenoson Stress for Myocardial Perfusion Imaging
Reyes, E. (2015) · Future Cardiology · doi:10.2217/fca.15.70 · Cited by 8 · see citing works
Caffeine Consumption and Heart Rate and Blood Pressure Response to Regadenoson
Bitar, A., Mastouri, R. A., & Kreutz, R. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130487 · Cited by 8 · see citing works
“In the coronary circulation, there is a high reserve for A2A receptor mediated coronary vasodilation with 25% receptor occupancy by regadenoson translating into 90% maximal vasodilation [10,28].”
BackgroundUpdate on myocardial perfusion imaging: role of regadenoson
Hendel, R. C. (2009) · Reports in Medical Imaging · doi:10.2147/rmi.s3978 · Cited by 6 · see citing works
Lee, C., Dennett, A. M., Pinson, J., & Lewis, A. K. (2024) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2023.12.011 · Cited by 5 · see citing works
Christian, T. F. (2016) · Journal of Nuclear Cardiology · doi:10.1007/s12350-016-0412-8 · Cited by 3 · see citing works
Regadenoson for myocardial perfusion scintigraphy
Reyes, E., & Pennell, D. J. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.506909 · Cited by 2 · see citing works
Adenosine–caffeine: the agonist—antagonist couple for vasodilator stress tests
Songy, B. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-03107-0 · Cited by 2 · see citing works
Physiologic and Pharmacologic Stressors
Miller, D. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5551-6_4 · Cited by 2 · see citing works
Pharmacologic Stress Using Selective A2A Adenosine Receptor Agonists
Hendel, R. C., Moreno, N. A., & Glover, D. K. (2011) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-011-9086-4 · Cited by 2 · see citing works
Cada, D. J., Levien, T. L., & Baker, D. E. (2009) · Hospital Pharmacy · doi:10.1310/hpj4401-57 · Cited by 1 · see citing works
Leiner, T. (2016) · International journal of cardiac imaging · doi:10.1007/s10554-016-0974-1 · Cited by 1 · see citing works
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00432-7 · Cited by 1 · see citing works
Central nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32001-0 · Cited by 1 · see citing works
Regadenoson myocardial perfusion imaging
Zoghbi, G. J., & Iskandrian, A. E. (2010) · Imaging in Medicine · doi:10.2217/iim.10.34 · Cited by 1 · see citing works
Pharmacologic Stress Agents for Cardiac Imaging
Reyes, E., & Anagnostopoulos, C. (2013) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-013-9212-6 · Cited by 1 · see citing works
“Regadenoson should not be given to patients reporting recent consumption of caffeinated products (<12 hours); contrary to an earlier report [46], a recent study suggests that caffeine does antagonise the vasodilator effect of regadenoson in a non-dose dependent manner [47].”
ResultMahmarian, J. J. (2011) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-011-9084-6
“One recent study with regadenoson showed no effect of 200 mg caffeine on regadenoson-induced coronary hyperemia as assessed by O15 water positron emission tomography [14].”
MethodHow Should We Stress the Human Heart?
Reyes, E. (2013) · Springer eBooks · doi:10.1007/978-88-470-2760-2_2
“Although recent caffeine consumption is a contraindication to regadenoson stress, a study in healthy volunteers suggests that at the recommended dose of 400 mcg, regadenoson may overcome the antagonism mediated by caffeine on the adenosine receptors [37].”
BackgroundRegadenoson — Overview of Applications in Cardiology
Palani, G., Baumann, R., & Ananthasubramaniam, K. (2015) · InTech eBooks · doi:10.5772/61154
“[16] Subsequent human studies evaluating myocardial blood flow in 41 healthy volunteers using REG with PET imaging showed that moderate caffeine consumption may not interfere with REG-induced coronary hyperemia.[17] Thus, conflicting evidence existed regarding the effect of caffeine on REG stress testing until a multi…”
BackgroundCerqueira, M. D. (2015) · doi:10.1093/med/9780199392094.003.0006
Kardiovaskuläre PET/CT in den USA
Schelbert, H. R. (2016) · Springer eBooks · doi:10.1007/978-3-662-48842-3_26
Physiologic and Pharmacologic Stressors
Miller, D. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-49885-6_5
Caffeine and SPECT Myocardial Perfusion Imaging
Tejani, F. H., & Konka, S. (2014) · Coffee in Health and Disease Prevention · doi:10.1016/b978-0-12-409517-5.00076-0
Cardiac PET Imaging in Coronary Artery Disease
Rikhi, R. R., & Dorbala, S. (2026) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2026.07.009
Kardiovaskuläre PET und PET/CT
Mohnike, W., Hör, G., & Schelbert, H. R. (2011) · Springer eBooks · doi:10.1007/978-3-642-17805-4_18
- Authors
- Gaemperli, O., Schepis, T., Koepfli, P., Siegrist, P. T., Fleischman, S., Nguyen, P., Olmsted, A., Wang, W., Lieu, H., & Kaufmann, P. A.
- Corresponding author
- Kaufmann, Philipp A.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 51
- Issue
- 3
- Pages
- 328-329
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W147864142
- Semantic Scholar
- fcd0f7a2c63ad2459f7efac3e2f8ce6e6d5cecf0
- Cited by
- 52
- References
- 9
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 1 · 2021: 3 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 8 · 2014: 2 · 2013: 3 · 2012: 6
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- National Science Foundation
- Astellas Pharma US
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (68835, 114706)
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Health Sciences › Medicine › Pharmacology › Coffee research and impacts
- Keywords
- caffeine, regadenoson, myocardial blood flow, adenosine A2A receptor, coronary vasodilation, drug interactions
- MeSH terms
- Caffeine, Coronary Circulation, Double-Blind Method, Drug Interactions, Heart Rate, Humans, Purines, Pyrazoles, Vasodilator Agents, Cross-Over Studies, Positron-Emission Tomography, Adenosine A2 Receptor Agonists, Adenosine A2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
